The study, published in JAMA Pediatrics on Monday, looked at private insurance claims representing over 5 million patients in the U.S. ages 8 to 17.

A new analysis of private insurance claims data finds less than 0.1% of youth accessed puberty blockers or hormones for gender transition. This small group has garnered a huge amount of attention from Republican lawmakers in recent years.

While opponents of gender-affirming care for trans youth often act as if such care is common and undertaken thoughtlessly, it’s actually quite rare, according to a new study. The study, published Monday in JAMA Pediatrics,

From 2018 through 2022, only 926 adolescents with a gender-related diagnosis received puberty blockers and 1,927 received hormones, suggesting that fewer than 0.1 percent of all youth in the database received these medications.